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Introduction: Multiple investigations often result in a lengthy
process from the onset of lung cancer–related symptoms until
diagnosis. An unpublished chart audit indicated suboptimal delays in
patients’ courses from onset of symptoms until diagnosis of cancer.
Methods: The Time to Treat Program was designed for patients
with clinical or radiographic suspicion of lung cancer. Pre- and
postimplementation data on median wait times were compared.
Results: From April 2005 to January 2007, 430 patients were
referred. After Time to Treat Program implementation, the median
time from suspicion of lung cancer to referral for specialist consul-
tation decreased from 20 days to 6 days, and the median time from
such referral to the actual consultation date decreased from 17 days
to 4 days. The median time from specialist consultation to computed
tomography scan decreased from 52 days to 3 days, and the median
time from computed tomography scan to diagnosis decreased from
39 days to 6 days. Overall, the median time from suspicion of lung
cancer to diagnosis decreased from 128 days to 20 days. Of all
patients in the Time to Treat Program, 33% were eventually diag-
nosed with lung cancer.
Conclusions: Time to Treat Program was effective in shortening the time
from suspicion of lung cancer to diagnosis and reduced time intervals at
each step in the process. Earlier diagnosis of lung cancer may allow
increased treatment options for patients and may improve outcomes.
Key Words: Lung cancer, Diagnostics, Process.
(J Thorac Oncol. 2007;2: 1001–1006)
Lung cancer is ranked first in terms of cancer incidence andcancer death in Canada and in the world.1 Clinical out-
comes are better for patients diagnosed at an earlier stage of
disease.2,3 Unfortunately, the course of diagnostic workup
from the onset of symptoms until the time of diagnosis is
often lengthy with delays resulting from serial investigations
and fragmented care. Undesirable wait times for consultative,
diagnostic, and cancer treatment services (surgery, radiation)
in Canada have been reported.4,5 An unpublished retrospec-
tive chart audit was conducted at the Toronto East General
Hospital (TEGH), a large urban community teaching hospital
servicing southeast Toronto in the province of Ontario, Can-
ada. Wait times in the diagnostic workup of lung cancer were
suboptimal. Reducing wait times is a key priority for the
provincial government and has resulted in the implementation
of the Ontario Wait Times Strategy.6
Given the significant global interest in wait time reduc-
tions, numerous demand-side and supply-side strategies for
reducing wait times have been implemented in several coun-
tries and have shown positive results.7 The National Health
Service (NHS) in the United Kingdom has illustrated the
ability to affect both the supply and demand of health care
services by focusing on process issues.8–10 In addition to
developing appropriate capacity, their strategy included a
number of elements for process improvement. The NHS
showed the importance of sustained focus on the task orga-
nizationally (through both management and clinical effort),
collecting and analyzing relevant detailed information, and
planning.
Based on the experience and the success of the NHS, a
proposed solution for local delays in lung cancer diagnostic
workup at the TEGH was proposed: the Time to Treat
Program. This system redesign was initially a pilot project
and consisted of a streamlined referral system and a clerical
facilitator to fast-track patients through a diagnostic pathway
algorithm.
METHODS
The TEGH Research Ethics Board granted approval of
this study.
Retrospective Chart Review
A retrospective chart audit of patients who had con-
firmed diagnoses of lung cancer made between March 2004
and February 2005 was studied. Interval wait times were
collected and analyzed. Based on the results of this audit, an
interested group of respirologists, thoracic surgeons, and
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oncologists came together to redesign the process whereby
patients with suspected lung cancer were referred and subse-
quently investigated.
Time to Treat Project
Referral
A single-entry point of contact and a new referral form
was developed to access the Time to Treat Program. The
respirologists and thoracic surgeons agreed on a set of criteria
as to which patients would be best suited to see either the
pulmonary specialist or the chest surgeon. The two-sided
referral form collected patient demographics, referring phy-
sician contact information, and the date of the suspicious
chest radiograph. It also asked the referring physician for the
reason for referral by way of a checklist menu that included
descriptions of possible chest radiograph abnormalities and
clinical symptoms. The back of the referral form had two
checklists: one of clinical features that should prompt an
urgent radiograph and the other of signs and symptoms to
guide referral to respirology versus thoracic surgery. The
referring physician was also reminded to send clinical notes,
including medications, and blood test results to the consultant
physician. The referring physician was also asked to help
ensure that patients bring their radiographs and computed
tomography (CT) scans to the initial subspecialty appoint-
ment. The referral sheets are faxed to a central booking clerk,
the “navigator.”
Navigator
The navigator was a new clerical position, and this
person was hired to coordinate the care of patients during
diagnostic workup. The navigator collected referrals,
booked initial consultations, facilitated investigation book-
ings, and recorded data relating to patient appointments
and investigations.
Diagnostic Algorithm
A new algorithm was developed entitled the “Lung
Cancer Pathway.” There were three possible ways for a
patient to enter the pathway: direct referral by a treating
clinician, by an in-house radiologist, or redirected into the
appropriate step in the pathway by a specialist who was
initially consulted in the standard model. At the time of
receiving the referral, the navigator booked the patient to see
an appropriate consultant. The navigator informed the refer-
ring physician’s office about the appointment times, and the
patient was informed of their appointment through that office.
At the time of entry to the program, a patient was also shadow
booked for a CT scan close to but after the date of the consult.
A patient could have their CT scan before the initial consult
date if the physician reviewing the referral form thought it
was appropriate. On the day of the initial visit, the patient
arrived, registered, and met with the consulting physician.
Spirometry was done immediately for all respirology refer-
rals. At this visit, there were then three possible next steps: no
further investigations required, referral to another subspe-
cialty service, or additional investigations including spirom-
etry. For each patient, these investigations included some or
all of the following: fine needle aspiration biopsy, bronchos-
copy, complete pulmonary function tests, and CT scan. There
were follow-up appointments to review the results of the
investigations.
Dedicated CT Scan Slots
CT scans were shadow booked at the time of referral to
the Program. Two daily CT scan slots were allotted to the
Time to Treat Program from the general pool. If these slots
were not used, they were reallocated to the hospital general
pool 48 hours before the time slot.
Dedicated Bronchoscopy Slots
There was pooling of bronchoscopy slots at TEGH
between the respirologists and the thoracic surgeons to ensure
even and shorter wait times.
Treatment Algorithm
There were multidisciplinary tumor boards involving
two hospitals, with representation from radiation oncology,
thoracic surgery, medical oncology, pathology, radiology,
and respirology services. During these weekly meetings,
cases of patients with early or locally advanced disease or
treatment issues were discussed. A standardized form was
developed for patient presentation. A new synoptic sheet was
developed to record each patient case.
Target Wait Times
Interval target wait times were set. The target wait time
for referral for a specialist consult was 5 or fewer working
days. The target wait time for CT scan was fewer than 10
working days.
Referral Base
The local family practice units, radiology department,
and potential referring physicians from the TEGH community
were educated about the Time to Treat Program. Physicians
were asked to give input into the new referral form. A
physician representative from each of the large local family
practice groups was asked to increase awareness of the Time
to Treat in their local centers.
Physician Satisfaction
Physician satisfaction surveys were performed. Refer-
ring physicians who referred eight or more patients to the
Time to Treat Program or physician representatives of a large
family practice group were asked to rate six items on a scale
of 1 to 5, with 5 being significantly better, 1 being signifi-
cantly worse, and 3 being neutral. These six items were ease
of referral to a specialist, ease of making initial investigation
booking, ease of tracking or changing investigations, com-
munication within the departments, quality of care for the
patient, and the patient-physician relationship.
Data Analysis
The dates of investigations and patient visits were
recorded and tracked in an electronic database by the navi-
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gator. Median wait times were compared before and after
Time to Treat Program implementation.
RESULTS
Preimplementation Data
From March 27, 2004 to February 1, 2005, 52 patients
were diagnosed with lung cancer at TEGH. These 52 patients
were referred from 44 different physicians between Novem-
ber 25, 2003 and June 5, 2004 for diagnostic workup and
clinical assessment.
As shown in Figure 1, the median time from date of
suspicious chest radiograph to referral was 20 days. The
median wait time from date of referral for consultation to
actual consultation date was 17 days. The time from consul-
tation date to CT date was 52 days and from CT to diagnosis
was 39 days. The overall length of time from suspicion of
lung cancer from abnormal chest radiograph to confirmed
diagnosis was 128 days.
Postimplementation Data
From April 5, 2005 to December 18, 2006, more than
120 physicians referred 430 patients: 193 females and 237
males. The mean age at time of referral to Time to Treat
Program was 66 years. For the majority of patients (95.7%),
the reason for referral was chest radiograph findings suspi-
cious for lung cancer.
The median time from suspicion of lung cancer to
referral for specialist consultation was 6 days (Figure 1), with
75% of patients being referred by 14.0 days and 90% of
patients by 27 days. The median time from such referral to
the actual consultation date was 4 days (Figure 1), with the
75% of patients being seen by 7 days and 90 % of patients by
10 days.
The median time from specialist consultation to CT
scan was 3 days (Figure 1), with a 75th percentile of 5 days
and a 90th percentile of 8 days. The median time from CT to
diagnosis was 6 days (Figure 1), with a 75th percentile of 15
days and a 90th percentile at 29 days. As shown in Figure 2,
overall the median time from suspicion of lung cancer to
diagnosis was 20 days. For 25% of the patients in the Time to
Treat Program, it took 11 or fewer days from suspicion of
lung cancer to diagnosis, whereas for 4% of the patients, it
took 90 days or longer.
The time from suspicion to diagnosis took longer for
patients who eventually had confirmed lung cancer than those
who did not: 37 days versus 29 days.
Satisfaction Survey Results
Of the 12 physicians contacted who had each referred
eight or more patients, one had retired and was not available.
Satisfaction survey results are shown in Table 1.
Three physicians commented on how they used to
admit patients with suspected lung cancer to expedite their
diagnostic workup, and after the Time to Treat Program
implementation, this practice pattern changed.
DISCUSSION
There were 22,700 new cases of lung cancer in Canada
in 2006. The 19,300 deaths from lung cancer last year were
greater than the combined total deaths from breast cancer,
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FIGURE 1. Pre- and postimplementation comparison of interval and overall wait times.
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prostate cancer, and colorectal cancer.11 Although this ma-
lignancy is potentially curable, it can progress quickly, and
thus timely diagnosis and management are considered part of
ideal care. The Time to Treat Program adapted success
process engineering from abroad to address local problems.
Outcomes
Individual services (e.g., radiology department, subspe-
cialty consults, family practice groups) were well established
and provided good quality care. However, stronger relation-
ships were required. The only new entities that the Time to
Treat Program created were stronger linkages between these
health care services. There were four core elements that
improved communication and multidepartment patient care
planning: streamlined referral, the navigator, algorithms (di-
agnostic and treatment), and dedicated investigation booking
slots. Due to these four core elements, the Time to Treat
Program was successful in decreasing the overall median wait
time and each interval median wait time, especially the
interval time to obtain a CT scan.
Clinical Relevance
In lung cancer, negative effects on stage translate to
large differences in 5-year survival in non-small cell lung
cancer with previously reported 5-year overall survival rates
of 66.5% for stage I patients,12 49.2% for stage II patients,13
35% for stage IIIA (T3N1) patients, 6% for stage IIIA
(T3N2) patients,14 5% for stage IIIB patients, and 1% for
stage IV patients.15 It is likely that earlier diagnosis would
lead to better clinical outcome.
Once patients are diagnosed with lung cancer and are
eligible for surgery, they undergo surgery in a timely fashion
at this institution. Earlier diagnosis leads to earlier manage-
ment. The Ontario Provincial Wait Time Strategy measures
the length of time from diagnosis of lung cancer until sur-
gery.16 During the past quarter, the provincial average wait
for lung surgery was 38 days measured as time from decision
to proceed with surgery until completion of surgery. The
same wait time for lung surgery at this institution was 23
days. The hospital with the shortest wait time for lung surgery
in the province had a wait time of 15 days. Currently, there is
no published evidence that decreasing diagnostic or treatment
wait times results in improved survival.
Is the lead time enough to result in a different stage at
presentation? Perhaps. Earlier or more rapid diagnostic
workup has been shown to increase therapeutic options in that
resection rates increased from 10% to 25% in the United
Kingdom17 and from 25% to 31% in the United States.18 A
study from Denmark in 1997 showed that a few months’
delay before treatment of non-small cell lung cancer had an
effect on the perioperative stage and therefore prognosis.19 It
is possible that even if rapid diagnostic workup does not
change the stage at presentation, it may still increase the
number of therapeutic options. Patients diagnosed earlier may
have a better Eastern Cooperative Oncology Group perfor-
mance status and be able to tolerate more aggressive inter-
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FIGURE 2. Time for patients to receiving diagnosis from suspicious chest radiograph.
TABLE 1. Provider Satisfaction Results
Item
% of Physicians Who Ranked
on Satisfaction Survey Better (4/5)
or Significantly Better (5/5)
Ease of referral to a specialist 100
Ease of initial bookings of
investigations
100
Change/track bookings of
investigations/visits
87.5
Communication with health
care system
72
Quality of care for patient 90
Patient-physician relationship 70
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ventions. Aside from surgery, patients with better perfor-
mance status may be better candidates for chemotherapy or
radiation.
Decreasing wait times has a positive impact on
patient anxiety,20 mental well-being,21 and satisfaction and
physical function.22 Clinically, patients may also benefit
from not having redundant investigations performed and
thus avoiding the potential side effects of redundant inves-
tigations. The two thirds of patients who did not have lung
cancer were told so more than 3 months earlier with the
Time to Treat Program. For these patients, there is likely a
significant quality-of-life benefit.
Two thirds of referrals did not have lung cancer. Cur-
rently at this hospital, the majority of patients who are
investigated for suspicion of lung cancer are found not to
have lung cancer. However, this may not be the case in other
centers. The authors believe that it is ideal to have the
minority of patients investigated actually found to have lung
cancer. If all patients investigated were found to have lung
cancer, the concern would be that insufficient numbers of
people were being screened. There are currently no data in
the literature on what the optimal suspicion threshold is for
investigations. It is a balance between investigating more
people and not missing any diagnosis of lung cancer and
using more resources versus investigating fewer people and
potentially missing some patients’ diagnosis but conserving
resources.
Other Potential Implications
In the large context of the entire health care system,
other potential benefits of the Time to Treat Program were
better use of the referring physicians’ time and office
resources.
The upside in terms of cost-benefit analysis may be
larger than what is initially apparent. Some referring physi-
cians have indicated that patients who used to be admitted for
the sole reason of expediting their diagnostic workup may
now be managed as an outpatient. Diverted patient admis-
sions decreased hospital costs.
It is unclear whether there is increased workload as it is
unclear whether more patients in this catchment area are
being investigated compared with before the Time to Treat
Program implementation. Family physicians were given a
guideline as to when patients should be referred to the Time
to Treat Program. It is possible that increased awareness
about lung cancer has increased referrals for investigations;
however, it is also possible that by following the distributed
guidelines, fewer patients with lower suspicion for lung
cancer are referred.
Challenges
The main challenges were access to investigations,
education, and sustainability. Access to diagnostic imaging is
an ongoing issue in this province, and the Time to Treat
Program required dedicated CT scan slots along with effec-
tive use of these slots. A system has to be set up to avoid
cannibalization of CT slots by returning unused slots to the
general pool. Also with almost all new projects, there was the
challenge of educating other healthcare departments and
referring physicians about the purpose and role of the Pro-
gram. Due to the dynamic nature of interval events, contin-
uous effort at each component of the Program was required to
ensure sustainability of shortened wait times.
Weaknesses
There are some recognized weaknesses of this study.
The preimplementation data are retrospective and have the
common downfalls of retrospective studies. The factors af-
fecting the before versus after Time to Treat Program cohort
of patients may have been different. Optimally, a randomized
study design would have allowed a better comparison be-
tween Program and non-Program cohorts.
Another consideration is that while most wait times are
involuntary, some are actually voluntary. Patients may not
show up or be available for appointments due to medical
reasons (e.g., hospitalization) or other reasons (e.g., vacation,
transportation, anxiety) reasons rather than the unavailability
of an appointment. In this study, we did not separate invol-
untary and voluntary waits. Information on the type of waits
is well captured on transplantation waiting lists and may be
adaptable to our future work.
Looking Ahead
It would be useful to understand the implications of the
Time to Treat Program for its own hospital services and also
for neighboring hospitals. Did the shortened time intervals
and multidisciplinary tumor board affect surgical, radiation,
or chemotherapy services?
Sharing Successful Strategies
Future endeavors include evaluating other local process
improvement initiatives. As a part of continual assessment
and response to change, the Time to Treat Program may
benefit from the experience of these other institutions. In
addition, the Time to Treat Program strategies may be effec-
tively adopted in another institution and may be adaptable to
the diagnostic workup of other malignancies.
Success will require support from institution adminis-
tration and provincial leaders. As illustrated from the expe-
rience of the National Health Service in the United Kingdom,
the work in this area was not a grassroots project, but rather
benefited from strong governmental direction.
Summary
The Time to Treat Program, a system redesign at a
community hospital, has been shown to be effective in de-
creasing wait times at each step of the pathway in the workup
of lung cancer. This study illustrated the importance of
evaluating and improving the process for optimal clinical
outcomes and potentially resource use. Continued motivation
and effort on this endeavor are necessary to maintain accept-
able wait times.
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